贾克替尼(一种新型JAK抑制剂)在芦可替尼不耐受的骨髓纤维化患者中的安全性和疗效:一项单臂、开放标签、2期、多中心研究
该2期多中心单臂研究纳入51例芦可替尼不耐受的骨髓纤维化患者,其中45例接受贾克替尼100 mg每日两次治疗。100 mg每日两次组第24周脾体积缩小≥35%的比例为43.2%(19/44,95%CI 29.7%-57.8%),最常见≥3级治疗中出现的不良事件为贫血31.1%、血小板减少22.2%和感染性肺炎17.8%。结果表明贾克替尼可为芦可替尼不耐受的骨髓纤维化患者提供治疗选择。
要点
- 100 mg每日两次组第24周脾体积缩小≥35%的比例为43.2%(19/44,95%CI 29.7%-57.8%)。
- 100 mg每日两次组第24周总症状评分降低≥50%的比例为61.8%(21/34)。
- 100 mg每日两次组最常见≥3级治疗中出现的不良事件为贫血31.1%、血小板减少22.2%、感染性肺炎17.8%。
核心结论
- 结果表明贾克替尼可为芦可替尼不耐受的骨髓纤维化患者提供治疗选择。
研究设计与样本
- 2期、单臂、开放标签、多中心研究,纳入51例芦可替尼不耐受的骨髓纤维化患者,45例接受贾克替尼100 mg每日两次治疗,6例接受非100 mg每日两次剂量。
- 研究时间为2019年12月18日至2021年11月24日。
主要发现
- 100 mg每日两次组第24周脾体积缩小≥35%的比例为43.2%(19/44,95%CI 29.7%-57.8%)。
- 100 mg每日两次组中,基线血红蛋白≤100 g/L且不依赖输血的31例患者中,41.9%(13/31)在24周内血红蛋白升高≥20 g/L。
- 100 mg每日两次组第24周总症状评分降低≥50%的比例为61.8%(21/34)。
- 100 mg每日两次组最常见≥3级治疗中出现的不良事件为贫血31.1%、血小板减少22.2%、感染性肺炎17.8%。
- 100 mg每日两次组中16例(35.6%)发生严重不良事件,其中4例(8.9%)被认为可能与药物相关。
关键数值与推荐
- 主要终点为第24周脾体积缩小≥35%的患者比例。
- 次要终点包括骨髓纤维化相关症状变化、贫血反应和安全性特征。
临床怎么用
- 原文结论认为贾克替尼可为芦可替尼不耐受的骨髓纤维化患者提供治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although ruxolitinib improves splenomegaly and constitutional symptoms in patients with myelofibrosis (MF), a substantial proportion of patients discontinue ruxolitinib because of intolerance. This phase 2 trial investigated the safety and efficacy of jaktinib, a novel JAK inhibitor in patients with ruxolitinib-intolerant MF. The primary endpoint was the proportion of patients with ≥35% reduction in spleen volume (SVR35) at week 24. The secondary endpoints included change of MF-related symptoms, anemic response, and safety profiles. Between December 18, 2019, and November 24, 2021, 51 patients were enrolled, 45 treated with jaktinib 100 mg bid (100 mg bid group) and six received non-100 mg bid doses (non-100 mg bid group). The SVR35 at week 24 in the 100 mg bid group was 43.2% (19/44, 95% CI 29.7%-57.8%). There were 41.9% (13/31) of transfusion-independent patients with hemoglobin (HGB) ≤100 g/L who had HGB elevation ≥20 g/L within 24 weeks. The proportion of patients with a ≥50% decrease in the total symptom score (TSS 50) at week 24 was 61.8% (21/34). The most commonly reported grade ≥3 treatment-emergent adverse events (TEAEs) in the 100 mg bid group were anemia 31.1%, thrombocytopenia 22.2%, and infectious pneumonia 17.8%. A total of 16 (35.6%) in the 100 mg bid group had serious adverse events, and 4 (8.9%) were considered possibly drug related. These results indicate jaktinib can provide a treatment option for patients with MF who are intolerant to ruxolitinib.
引用
- Zhang Y, Zhou H, Duan M, et al. Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. Am J Hematol. 2023. PMID: 37470365. doi:10.1002/ajh.27033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。